MentionFox
Home › Executive changes › Idexx Laboratories Inc /De
Leadership changes · IDXX · SEC Form 8-K, Item 5.02

Leadership changes at Idexx Laboratories Inc /De (2026)

Before you join, sell to or invest in Idexx Laboratories Inc /De

MentionFox check on Idexx Laboratories Inc /De: no red flags found in 3 sources (checked 14 November 2026). mentionfox.com/c/executive-changes/idexx-laboratories-inc-de

Check Idexx Laboratories Inc /De before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Idexx Laboratories Inc /De?

Who joined and who left Idexx Laboratories Inc /De (IDXX)? 3 filings reported from 2026-01-13 to 2026-03-26, each cited to the company's own filing.

As of November 14, 2026, Idexx Laboratories Inc /De has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from January 13, 2026 to March 26, 2026 (Form 8-K, March 26, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Vanguard Portfolio Management also filed stake reports on 941 other companies ↓

Sell to companies like Idexx Laboratories Inc /De? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Key facts

  • · In / out: Reported · Person: not named in the filing · 8-K, 2026-03-26
  • · In / out: Reported · Person: not named in the filing · 8-K, 2026-02-13
  • · In / out: Reported · Person: not named in the filing · 8-K, 2026-01-13
Changes3
Latest filing2026-03-26

Idexx Laboratories Inc /De reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-01-13 to 2026-03-26. Every row below is cited to the filing it comes from, and this page adds each new change as Idexx Laboratories Inc /De files it.

Also on the record for Idexx Laboratories Inc /De

DateRecordFigureOur pageSource
October 30, 2026Stake report, Schedule 13G, by Vanguard Portfolio Management5.04% of the class5%+ stakesSource
April 30, 2026Stake report, Schedule 13G, by Vanguard Capital Management7.51% of the class5%+ stakesSource
March 27, 2026Stake report, Schedule 13G/A, by The Vanguard Group—5%+ stakesSource

Selling to them or working with them? See who runs Idexx Laboratories Inc /De now and the warning signs.

Free to see. No signup.

Keep reading

More on Idexx Laboratories Inc /De and the records around it.

Companies that share a holder

Want the whole picture on Idexx Laboratories Inc /De?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Idexx Laboratories Inc /De: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Idexx Laboratories Inc /De covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    6 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-03-26Reportednot named in the filing8-K, 2026-03-26
2026-02-13Reportednot named in the filing8-K, 2026-02-13
2026-01-13Reportednot named in the filing8-K, 2026-01-13
Selling to Idexx Laboratories Inc /De?

New leaders reset buying decisions — get the Full Report on Idexx Laboratories Inc /De: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Idexx Laboratories Inc /De

Hiring for a seat like this?

Find people with the same kind of experience as the senior executive at Idexx Laboratories Inc /De, with the record behind each one.

Find candidates like senior executive at Idexx Laboratories Inc /De

Every change, in the filing's words

Filed 2026-03-26 · 8-K

Reported

On March 24, 2026, IDEXX Laboratories, Inc. ("IDEXX") and Nimrata Hunt, PhD, Executive Vice President, Global Strategy and Commercial, mutually agreed that Dr. Hunt will cease serving in her current role effective on April 13, 2026 (the "Separation Date") and will continue to provide advisory services on an as-needed basis until July 13, 2026 (the "Final Employment Date").

Also stated in this filing

  • IDEXX and Dr. Hunt entered into a separation letter agreement (the "Separation Agreement") to memorialize the terms of Dr. Hunt's advisory role and subsequent departure.
  • Vesting of stock option, restricted stock unit and performance stock unit awards previously issued to Dr. Hunt under IDEXX's stock incentive plans will cease effective as of the Final Employment Date, and all unvested awards will be forfeited.
  • Dr. Hunt's stock option awards, to the extent vested and exercisable, will remain exercisable during the period following the Final Employment Date that is specified in the applicable award agreements.
  • Dr. Hunt's position with IDEXX is being eliminated, and, as a result, IDEXX deems Dr. Hunt's separation to be a termination of employment without cause for purposes of determining Dr. Hunt's separation benefits.
  • The Separation Agreement also contains a general release of claims in favor of IDEXX (including a reaffirmation thereof on or following the Separation Date and on or following the Final Employment Date), non-disparagement and continuing cooperation covenants and an acknowledgement by Dr. Hunt that she continues to be bound by restrictive covenants applicable to her under the Confidential Information, Work Product, and Restrictive Covenant Agreement between her and IDEXX dated January 24, 2022.
Filed 2026-02-13 · 8-K

Reported

(b) On February 13, 2026, Ms. M. Anne Szostak provided IDEXX Laboratories, Inc. (the "Company") notice of her intention to retire from the Board of Directors (the "Board") effective immediately following the Company's 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting") to be held on May 12, 2026.

Also stated in this filing

  • Ms. Szostak's decision to retire from the Board does not arise from any disagreement with the Company or the Board on any matter relating to the Company's operations, policies, practices or otherwise.
  • The Company thanks Ms. Szostak for her extraordinary service, contributions and leadership during her tenure as a member of the Board since 2012.
Filed 2026-01-13 · 8-K

Reported

On January 11, 2026, Jonathan (Jay) Mazelsky notified IDEXX Laboratories, Inc. (the "Company" or "IDEXX") of his intent to step down as the Company's President and Chief Executive Officer effective as of May 12, 2026 (the "Transition Date") and retire from the Company and the Company's Board of the Directors (the "Board") immediately following the Company's annual meeting of shareholders in May 2027 (the "Retirement Date").

Also stated in this filing

  • On January 13, 2026, the Company announced that effective as of the Transition Date Mr. Mazelsky will transition to the role of Executive Chair of the Board and Michael (Mike) Erickson, PhD, will assume the role of President and Chief Executive Officer of the Company and join the Board as a Class II Director.
  • In his capacity as President and Chief Executive Officer, Dr. Erickson will serve as the Company's principal executive officer.
  • Mr. Mazelsky will work closely with Dr. Erickson until Mr. Mazelsky's Retirement Date to support a seamless transition.
  • Mr. Lawrence D. Kingsley, currently serving as the Board's independent Non-Executive Chair, will serve as independent Lead Director effective as of the Transition Date.
  • Dr. Erickson, 52, brings nearly two decades of leadership experience and significant healthcare technology and innovation expertise.
  • Since joining IDEXX in 2011, he has held senior positions across key portions of the Company's business, including diagnostics, software, strategy and corporate accounts, and currently serves as Executive Vice President and General Manager of IDEXX's Global Point of Care Diagnostics and Telemedicine lines of business.
  • Prior to joining the Company, Dr. Erickson advised leading pharmaceutical, biotechnology and health service companies as an Associate Principal at McKinsey & Company.

Tools for this story

Each opens in a new tab, filled in for Idexx Laboratories Inc /De. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/idexx-laboratories-inc-de
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
What changed at the top of Idexx Laboratories Inc /De?. MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/idexx-laboratories-inc-de